Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,501 | -29,745 | -22,003 | -24,526 | -69,920 |
| Depreciation Amortization | 363 | 352 | 341 | 330 | 1,380 |
| Accounts receivable | 1,375 | 1,504 | 1,384 | 1,227 | -633 |
| Other Working Capital | -10,023 | -11,821 | -12,971 | 5,269 | -2,829 |
| Other Operating Activity | 2,149 | 4,753 | 4,109 | 4,309 | 7,152 |
| Operating Cash Flow | $-39,637 | $-34,957 | $-29,140 | $-13,391 | $-64,850 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 15,216 | 16,932 | 26,951 | 11,349 | 23,130 |
| PPE Investments | 364 | 9 | 9 | N/A | -182 |
| Investing Cash Flow | $15,580 | $16,941 | $26,960 | $11,349 | $22,948 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,721 | 4,081 | 3,237 | 2,784 | 51,996 |
| Financing Cash Flow | $5,721 | $4,081 | $3,237 | $2,784 | $51,996 |
| Exchange Rate Effect | 14 | 13 | 25 | 4 | -49 |
| Beginning Cash Position | 36,330 | 36,330 | 36,330 | 36,330 | 26,285 |
| End Cash Position | 18,008 | 22,408 | 37,412 | 37,076 | 36,330 |
| Net Cash Flow | $-18,322 | $-13,922 | $1,082 | $746 | $10,045 |
| Free Cash Flow | |||||
| Operating Cash Flow | -39,637 | -34,957 | -29,140 | -13,391 | -64,850 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -182 |
| Free Cash Flow | -39,637 | -34,957 | -29,140 | -13,391 | -65,032 |